If you are not happy with the results below please do another search
With a distinguished and award-winning career at companies such as Ogilvy Health and McCann Health, Basque brings creative support, refined technique, and 25 years of expertise to The Bloc, further strengthening its commitment to health communication excellence.
Yesterday the agency denied approval for Abeona Therapeutics’ investigational gene-corrected cell therapy prademagene zamikeracel (pz-cel) for the treatment of recessive dystrophic epidermolysis bullosa, a rare disease that causes painful blistering and erosion of the skin.
CEO Hervé Hoppenot said on an investor call that Escient Pharmaceuticals’ two lead assets “address large populations with a clear medical need” with a potential multibillion-dollar market opportunity.
DeViteri previously spent nearly 20 years at Inizio Evoke Comms and returns after close to two years at MSL, where she successfully partnered with leadership to strengthen and grow its health practice. Over the course of her career, she’s led the creation and execution of countless health communications programs and initiatives, with people and communities always at the center.
Data from the Phase III LUNA 3 study on Tuesday showed that Sanofi’s BTK inhibitor rilzabrutinib significantly improved durable platelet response in patients with chronic immune thrombocytopenia.
Nine months into the U.S. launch of the first drug proven to slow the advance of Alzheimer’s, Eisai and Biogen’s Leqembi is facing an unexpected hurdle to widespread use: an entrenched belief among some doctors that treating the memory-robbing disease is futile.
Pfizer and BioNTech asked a London court to revoke rival Moderna’s patents over technology key to the development of vaccines for COVID-19, as the latest leg of a global legal battle began on Tuesday.
Swiss drugmaker Novartis raised its full-year guidance on wider use of psoriasis and arthritis drug Cosentyx on Tuesday and said it had tapped the former boss of Bristol Myers Squibb to become its chairman next year.
The agency’s green light is a shot in the arm for ImmunityBio, which had reiterated doubts in a regulatory filing last month about its ability to remain in business.
Boehringer Ingelheim is paying $35 million in upfront and near-term fees to work with Ochre Bio to identify and validate regenerative targets for metabolic dysfunction-associated steatohepatitis and other chronic liver diseases.
